TY - JOUR
T1 - Antineoplastic drug induced nausea and vomiting
T2 - What is the clinical practice in 2018? An update of AFSOS clinical guidelines
AU - Groupe de travail du référentiel Association francophone pour les soins oncologiques de support (AFSOS) sur les nausées-vomissements induits par les traitements anti-cancéreux
AU - Jovenin, Nicolas
AU - Eche-Gass, Audrey
AU - Chèze, Stéphane
AU - Launay-Vacher, Vincent
AU - Mayeur, Didier
AU - Rey, Jean Baptiste
AU - Joly, Florence
AU - Krakowski, Ivan
AU - Scotté, Florian
N1 - Publisher Copyright:
© 2019 Société Française du Cancer
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti–emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) “Outperform” prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed.
AB - Antineoplastic drug induced nausea and vomiting (ANDINV) (previously named: Chemotherapy-induced nausea and vomiting [CINV]) are one of the most feared adverse effect for patients who begin treatment with anti-cancer treatments and their bad control have a negative impact in the management of these patients. In this review article, it is proposed an update of French-speaking Association for oncologic supportive care (AFSOS) clinical practice of CINV guidelines. This update became necessary for several reasons: newly available anti–emetic drugs; new data published about individual risk factors of CINV; new antineoplastic agents available; changing in emetic risk levels for some molecules in the international guidelines. To address these guidelines, the various clinical presentations of ANDINV and their intensity classification are discussed. Then, the different therapeutic solutions are presented: classes of conventional drug therapies, complementary therapies and advice to patients. Then, the implementation of primary prophylaxis are presented in four steps: (1) to evaluate the emetic risk level of antineoplastic agent; (2) to set the emetic risk level of antineoplastic protocols; (3) to set types of antiemetic drugs to implement; (4) “Outperform” prophylaxis in case of individual risk factors. Finally, implementation of secondary prophylaxis and rescue treatments are adressed.
KW - Antineoplastic agents
KW - Guidelines
KW - Nausea
KW - Supportive care
KW - Vomiting
UR - http://www.scopus.com/inward/record.url?scp=85063197599&partnerID=8YFLogxK
U2 - 10.1016/j.bulcan.2019.02.002
DO - 10.1016/j.bulcan.2019.02.002
M3 - Review article
C2 - 30922554
AN - SCOPUS:85063197599
SN - 0007-4551
VL - 106
SP - 497
EP - 509
JO - Bulletin du Cancer
JF - Bulletin du Cancer
IS - 5
ER -